Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Bio Green Med Solution (NASDAQ: BGMS): Understanding the Fire-Safety Company's Pending Merger

Bio Green Med Solution, Inc (NASDAQ: BGMS) is headquartered in Kuala Lumpur, Malaysia, and operates in the industrials sector. Its business centers on distributing, trading and installing protective and fire-safety materials and equipment, along with fire protection and prevention systems. Despite the "Med" in …

Nitish Kishor | 10 September 2026

Rafarma Pharmaceuticals (OTC: RAFA): A Sub-Penny Generic Drugmaker's Limited Disclosure

Rafarma Pharmaceuticals describes itself as a multi-product pharmaceutical company focused onManufacturingand selling generic antibiotics, specialty medicines and anti-cancer drugs, with operations oriented toward Russian and international markets. The company is incorporated in Wyoming and its shares trade on the OTC Markets rather than a …

Nitish Kishor | 10 September 2026

Change Agents Corporation (NASDAQ: CHGA): Inside the Company's Reverse Stock Split

Change Agents Corporation is a developer of agentic artificial-intelligence software aimed at small businesses and content creators. Its products include Beacon, described as an AI search-optimization platform, and Catch-Up, an autonomous content-creation tool, both offered through a software-as-a-service model. The company also distributes KetoAir, …

Nitish Kishor | 10 September 2026

Niagen Bioscience (NASDAQ: NAGE): From Consumer Supplements to Rare-Disease Development

Niagen Bioscience develops and markets nicotinamide riboside chloride, branded Niagen, in both food-grade and pharmaceutical-grade formulations, with Tru Niagen as its best-known consumer product. The company trades on theNasdaqunder the ticker NAGE following its rebranding from ChromaDex, a change investors should keep in mind …

Nitish Kishor | 10 September 2026

Anavex Life Sciences (NASDAQ: AVXL): Blarcamesine's Regulatory Path in Focus

Anavex is a clinical-stage biotechnology company listed on theNasdaqunder AVXL, developing oral small-molecule therapies for central-nervous-system disorders. Its lead candidate, blarcamesine (ANAVEX2-73), a sigma-1 receptor agonist, is being advanced for early Alzheimer's disease, with additional programs in Rett syndrome and Fragile X syndrome.

Nitish Kishor | 10 September 2026

Akebia Therapeutics (NASDAQ: AKBA): Vafseo's Growth Against Auryxia's Decline

Akebia Therapeutics is a biopharmaceutical company focused on kidney disease, listed on theNasdaqunder AKBA. Its commercial portfolio is anchored by Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia due to chronic kidney disease in adults on dialysis, alongside Auryxia, an established phosphate-binder product now …

Nitish Kishor | 10 September 2026

Upstream Bio (NASDAQ: UPB): Verekitug Moves Into Pivotal Phase 3 Testing

Upstream Bio is developing verekitug, a monoclonal antibody that blocks the receptor for thymic stromal lymphopoietin (TSLP), an upstream driver of inflammation implicated across respiratory disease. On September 1, 2026, the company announced pivotal Phase 3 development plans for verekitug in both severe asthma …

Nitish Kishor | 10 September 2026

Matinas BioPharma (NYSE American: MTNB): The Deal Reshaping the Company Into Clean Energy

Matinas BioPharma built its reputation on a lipid nanocrystal (LNC) delivery platform and its lead candidate MAT2203, an oral formulation of the antifungal amphotericin B aimed at serious invasive fungal infections. On July 13, 2026, the company changed course dramatically. It signed a definitive …

Nitish Kishor | 10 September 2026

Eagle Pharmaceuticals (OTC: EGRX): From Nasdaq Drugmaker to Distressed Micro-Cap

Eagle Pharmaceuticals historically built its portfolio around injectable and specialty hospital products, including established franchises in oncology support and critical-care medicines, alongside efforts to broaden its pipeline. The company's trajectory changed sharply in 2024, when it disclosed that it had fallen behind on required …

Nitish Kishor | 10 September 2026

YourWay Cannabis Brands (OTC: YOURF): A Snapshot of a Distressed Sub-Penny Stock

YourWay Cannabis Brands describes itself as a company that, through subsidiaries, manufactures, distributes and sells cannabis in the U.S. recreational and medicinal markets. It is a Canadian-incorporated entity, tied to Vancouver, British Columbia, with a U.S. operational presence associated with Phoenix, Arizona, and its …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…